Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    20 Hydroxyecdysone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biophytis Announces Successful Industrial Transfer Of BIO101 Production To Seqens
    Biophytis Announces Successful Industrial Transfer Of BIO101 Production To Seqens

    12 Jun 2024

    // PRESS RELEASE

    https://www.biophytis.com/en/biophytis-announces-the-successful-industrial-transfer-of-bio101-20-hydroxyecdysone-production-by-its-service-provider-seqens/

    PRESS RELEASE
    12 Jun 2024
    Share Share
    Biophytis has Requested Pre-Submission Meeting with FDA for EUA of Sarconeos
    Biophytis has Requested Pre-Submission Meeting with FDA for EUA of Sarconeos

    20 Jul 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=769306&lang=en

    ACCESSWIRE
    20 Jul 2023
    Share Share
    Biophytis has Filed with the HAS an Application for EAA for Sarconeos
    Biophytis has Filed with the HAS an Application for EAA for Sarconeos

    26 May 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=757514&lang=en

    ACCESSWIRE
    26 May 2023
    Share Share